Using special molecules to visualize and target brain cells involved in Alzheimer's disease
Molecular probes to image and target the neurovascular unit in health and disease
This study is looking at new tiny molecules that can help deliver drugs and imaging tools directly to important brain cells, which could improve treatments for conditions like Alzheimer's disease and stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10745915 on NIH RePORTER |
What this research studies
This research focuses on developing unique small molecules that can specifically target and enter different types of brain cells, such as endothelial cells, astrocytes, and pericytes, which are crucial for maintaining the blood-brain barrier. By understanding how these molecules are transported into cells, the researchers aim to create tools for imaging and delivering drugs directly to affected areas in the brain. The study will explore the use of these molecules for both imaging techniques like PET scans and as carriers for therapeutic drugs in conditions like Alzheimer's disease and stroke.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or related neurological conditions.
Not a fit: Patients with neurological disorders unrelated to the blood-brain barrier or those not diagnosed with Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved imaging techniques and targeted drug delivery for patients with Alzheimer's disease and other neurological disorders.
How similar studies have performed: Other research has shown promise in using targeted molecular probes for imaging and drug delivery, indicating potential success for this novel approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Grutzendler, Jaime — Yale University
- Study coordinator: Grutzendler, Jaime
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.